Ukrain

Lore & Background

Ukrain was created in 1978 by Vasyl Novytskyi, a famed Ukrainian chemist. The substance is derived from the plant Chelidonium majus, commonly known as celandine, and is produced by the Austrian company Nowicky Pharma. It has been promoted as a treatment for cancer and viral infections including HIV and hepatitis, but has not been approved by the US Food and Drug Administration.

In 2005, Edzard Ernst led a review of evidence for Ukrain's effectiveness. While the review found some evidence suggesting the drug was effective, it concluded that 'numerous caveats prevent a positive conclusion.' Ernst later noted that the trials were very small, often seemed to include Novytskyi himself, and had significant methodological flaws. Despite this, the article became much cited.

Legal incidents have surrounded the drug. In September 2012, Novytskyi and others were arrested in Austria for distributing Ukrain under suspicion of commercial fraud. In January 2015, Novytskyi appeared in Vienna regional court for selling Ukrain, earning an estimated 1.1 million euros through fraud by changing labels on expired vials. In March 2015, two co-defendants were exonerated, while proceedings continued for Novytskyi.

Reader's Guide

Ukrain represents a controversial chapter in alternative cancer treatments. Created in 1978 by Ukrainian chemist Vasyl Novytskyi, the drug has been promoted for cancer and viral infections but lacks scientific validation. The American Cancer Society and Memorial Sloan-Kettering Cancer Center state that available evidence does not support claims of effectiveness in treating cancer. A 2005 review led by Edzard Ernst found evidence that seemed 'too good to be true,' with small trials, methodological flaws, and apparent involvement of the drug's creator. Despite cautious conclusions, the review was widely cited. Legal troubles have further undermined the drug's credibility: Novytskyi was arrested in Austria in 2012 for commercial fraud, and in 2015 faced charges for earning 1.1 million euros by relabeling expired vials. In the United States, a licensed naturopath in Tucson, Arizona, was reprimanded for using Ukrain to treat cancer patients. The drug remains unapproved by the US Food and Drug Administration, and adverse side effects including hepatitis and allergic skin reactions have been reported. Ukrain's legacy is one of unsubstantiated claims, legal controversy, and a cautionary tale about the need for rigorous clinical trials.

Did You Know?

• Ukrain is named after the nation of Ukraine.
• A 2005 review led by Edzard Ernst found the trials were very small and often seemed to include Novytskyi himself.

Origins & Development

Ukrain, also known by its botanical name celandine, is a semi-synthetic compound derived from the plant Chelidonium majus. It was developed in 1978 by Vasyl Novytskyi, a well-known Ukrainian chemist, and has since been manufactured by the Austrian firm Nowicky Pharma. The name itself is a direct nod to the nation of Ukraine, reflecting its origin story. The substance is marketed as a therapeutic agent targeting a range of serious conditions, most notably cancer, but also viral infections such as HIV and hepatitis. Despite its broad promotional claims, Ukrain has never received approval from the United States Food and Drug Administration, meaning it operates in a regulatory gray zone in many jurisdictions. Its production and distribution are centered in Austria through Nowicky Pharma, yet its reach has extended into other countries, where it has been used in alternative medical settings. The combination of a plant-based origin, a national namesake, and ambitious therapeutic claims has made Ukrain a uniquely polarizing figure in the landscape of experimental and complementary medicine.

Scientific Scrutiny

The scientific community has subjected Ukrain to careful examination, and the results have been consistently discouraging. In 2005, researcher Edzard Ernst led a review of the available evidence. While the review acknowledged data that might suggest some effectiveness, it simultaneously concluded that numerous caveats made a positive determination impossible. Ernst later reflected on the experience in his personal blog, describing the underlying trial results as seeming "too good to be true." Upon closer inspection, he found the studies to be very small in scale, frequently involving Novytskyi himself as a participant, and riddled with significant methodological weaknesses. The Memorial Sloan-Kettering Cancer Center has maintained that no clinical trial has demonstrated the safety or effectiveness of the compound. Similarly, the American Cancer Society stated in 2013 that the available scientific evidence does not support claims of efficacy in treating human cancer. Beyond the absence of positive results, Ukrain has been linked to adverse reactions, including hepatitis and allergic skin reactions, adding a layer of risk to an already unproven therapy.

Legal & Regulatory Confrontations

Ukrain's path through the legal and regulatory landscape has been marked by repeated confrontations with authorities. The compound has never been approved by the US Food and Drug Administration, leaving it in a status of unregulated use in American jurisdictions. In September 2012, Novytskyi and several associates were arrested in Austria on suspicion of commercial fraud related to the drug's distribution. The legal troubles continued into 2015, when Novytskyi appeared before a Vienna regional court facing charges of selling Ukrain and generating an estimated 1.1 million euros through fraudulent means, specifically by relabeling expired vials. In March of that year, two of his co-defendants were cleared of the fraud charges, while proceedings against Novytskyi remained ongoing. The drug's unauthorized use also drew attention in the United States. Between October 2013 and April 2014, a licensed naturopath in Tucson, Arizona, named Michael Uzick, was administering Ukrain to cancer patients. A former employee, Britt Marie Hermes, reported the practice after discovering the unapproved substance was being imported. The Arizona Naturopathic Physicians Medical Board issued Uzick a formal letter of reprimand.

Legacy & Enduring Controversy

Ukrain occupies a peculiar and uncomfortable position in medical history. It is listed alongside other ineffective cancer treatments, a categorization that underscores the consensus of major medical institutions. The irony of its reception is captured in Ernst's retrospective observation: despite his own cautious and ultimately negative conclusion, the 2005 review article became widely cited, and Ernst mused that Novytskyi "must have been delighted" by the attention. This dynamic, where even a skeptical review grants a degree of legitimacy, highlights how difficult it is to fully discredit a substance that has been in circulation for decades. The compound's legacy is further complicated by its documented adverse effects, including hepatitis and allergic skin reactions, meaning that patients who sought it as a last-resort therapy may have suffered real harm without any proven benefit. Novytskyi's continued legal battles in Austria, the arrests, the fraud allegations involving relabeled expired vials, and the reprimand issued to an American naturopath all paint a picture of a product that has outlived any credible scientific support yet persists in the margins of alternative medicine.